Results 51 to 60 of about 280,401 (218)

Diagnostic accuracy of short-time inversion recovery sequence in Graves' ophthalmopathy before and after prednisone treatment [PDF]

open access: yes, 2014
Introduction: In Graves' Ophthalmopathy, it is important to distinguish active inflammatory phase, responsive to immunosuppressive treatment, from fibrotic unresponsive inactive one.
Belfiore, M. P.   +8 more
core   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

open access: yesActa Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset   +13 more
wiley   +1 more source

“Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity”

open access: yesClinical Ophthalmology, 2022
Jasenka Petrovic Jurcevic,1 Marko Jurcevic,2 Mateja Jagic,3 Anamarija Jazbec,4 Kresimir Mandic,5 Jelena Juri Mandic5 1Medical School University of Zagreb, PhD Candidate on the Programme “Biomedicine and Health”, Zagreb, Croatia; 2University of Zagreb ...
Petrovic Jurcevic J   +5 more
doaj  

Analysis in Choroidal Thickness in Patients with Graves' Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography

open access: yesJournal of Ophthalmology, 2018
Objectives The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves' ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT).
Nan Yu   +5 more
semanticscholar   +1 more source

Miosite do músculo reto medial como forma atípica de apresentação de linfoma tipo MALT: relato de caso [PDF]

open access: yes, 2014
Here we describe the rare case of a 55-year-old man with medial rectus muscle myositis as an atypical presentation of non-Hodgkin B-cell mucosa-associated lymphoma (MALT).
Dittrich, Mirtha Alicia Ramirez   +4 more
core   +4 more sources

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang   +16 more
wiley   +1 more source

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

open access: yesCase Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta   +17 more
doaj   +1 more source

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

open access: yesTaiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang   +3 more
doaj   +1 more source

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

open access: yesInternational Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu   +3 more
wiley   +1 more source

Current and Future Treatments for Graves’ Disease and Graves’ Ophthalmopathy

open access: yesHormone and Metabolic Research, 2018
The course and pathogenesis of Graves’ disease and Graves’ ophthalmopathy are interdependent, influencing each other’s therapeutic choices. Multiple factors including geographic location, access to medical services, patient and physician preferences ...
A. Kotwal, M. Stan
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy